Literature DB >> 787431

Clinical presentations and mechanisms of necrotizing angitis of the skin.

N A Soter.   

Abstract

Cutaneous necrotizing angiitis may be present as either palpable purpura or less commonly as recurrent urticaria, and each clinical presentation may be associated with hypocomplementemia or a normal complement system. A variety of mechanisms may be operative in the production of necrotic vascular skin lesions that appear as similar, recognizable morphologic lesions. These mechanisms include immune complexes, cellular-type hypersensitivity reactions, and initiation or modulation by mast cells. Two cellular patterns have been recognized in the skin of patients with cutaneous necrotizing angiitis that can be correlated with the involvement of the complement system in serum. In patients with hypocomplementemia, there is an infiltrate of neutrophils that is consistent with a process involving immune complexes; in patients with normocomplementemia there are lymphocytes and activated lymphocytes consistent with participation in part by cellular mechanisms. In both the hypocomplementemic and normocomplementemic forms and as well as in a unique patient in whom the mast cell may initiate the venular damage, the mast cell, which its content of chemical mediators, has the capacity to initiate as well as modulate subacute and chronic vascular damage.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 787431     DOI: 10.1111/1523-1747.ep12514705

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

Review 1.  Circulating immune complexes in dermatologic disease.

Authors:  T J Lawley; R P Hall
Journal:  Springer Semin Immunopathol       Date:  1981

2.  Paraproteinaemia in erythema elevatum diutinum.

Authors:  P M Kövary; H Dhonau; R Happle
Journal:  Arch Dermatol Res       Date:  1977-12-12       Impact factor: 3.017

3.  Circulating immune complexes in cutaneous vasculitis. Detection with C1q and monoclonal rheumatoid factor.

Authors:  S E Mackel; G Tappeiner; H Brumfield; R E Jordan
Journal:  J Clin Invest       Date:  1979-12       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.